Hydromorphone

BreastfeedingPediatric
  • TRADE NAMES: Dilaudid (AbbVie); Dilaudid-HP; Exalgo (Mallinckrodt); HydroStat IR; Jurnista (Janssen-Cilag); Palladone (Napp)
  • INDICATIONS: Pain
  • CLASS: Opiate agonist
  • HALF-LIFE: 1–3 hours; 2 hours (IV)
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:

Alcohol, Alvimopan, Ammonium chloride, Amphetamines, Anticholinergics, Anxiolytics and hypnotics, Buprenorphine, Butorphanol, Cimetidine, CNS depressants, Desmopressin, Domperidone, Droperidol, Linezolid, MAO inhibitors, Metoclopramide, Moclobemide, Nalbuphine, Pegvisomant, Pentazocine, Phenothiazines, Sodium Oxybate, SSRIs, St John's Wort, Succinylcholine, Thiazide diuretics

PREGNANCY CATEGORY: C

NOTE

OROS hydromorphone prolonged release (Jurnista) is a once-daily formulation of hydromorphone that utilizes OROS (osmotic-controlled release oral delivery system) technology to deliver the drug at a near constant rate.

BLACK BOX WARNING
ADDICTION, ABUSE, AND MISUSE; LIFE-THREATENING RESPIRATORY DEPRESSION; ACCIDENTAL INGESTION; NEONATAL OPIOID WITHDRAWAL SYNDROME; and INTERACTION WITH ALCOHOL

See full prescribing information for complete boxed warning.

Our database has 42 adverse reactions for this drug across the following areas

Please login to see the rest of this drug profile


Not a subscriber? Click here to subscribe

SKIN.
MUCOSAL.
CARDIOVASCULAR.
CENTRAL NERVOUS SYSTEM.
ENDOCRINE/METABOLIC.
GASTROINTESTINAL/HEPATIC.
NEUROMUSCULAR/SKELETAL.
RESPIRATORY.
OTHER.


Page last updated 07/31/2023

Drug Eruption Mobile Site

Symbol key

Incidence info

  • <1%
  • 1-5%
  • 5-10%
  • 10-15%
  • 15-20%
  • 20-30%
  • >30%

Seriousness info

  • Hospitalization possible
  • Life threatening
  • Fatal

Warnings in other populations info

  • Breast feeding
  • Geriatric
  • Pediatric
^ Back to top